# Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

> **NCT01368263** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 8 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** goserelin acetate
- **DRUG:** letrozole
- **DRUG:** anastrozole
- **DRUG:** chemotherapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT01368263
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to funding source and lack of accrual
- **Last updated:** 2015-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368263, "Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01368263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*